Yapay Zekâ Altın Çağını Bitirebilir mi? Bitcoin İçin Yeni Bir Dönem Başlıyor!

Yapay zekanın sınırlarına mı dayanıyoruz? Bitcoin ise tam tersine yeni bir patlama yaşamaya hazırlanıyor.

Teknoloji Duvarı

AI sistemleri artık veri açlığını doyuramıyor - eğitim için temiz veri kaynakları tükeniyor. Yapay zeka şirketleri lisans anlaşmalarında çıkmaza girdi. Regülasyonlar her geçen gün daha da sıkılaşıyor.

Dijital Altın Yükselişi

Bitcoin tam bu kaosta parlayacak gibi görünüyor. Geleneksel finans sisteminden kaçış arttıkça, dijital varlıklar güvenli liman haline geliyor. Kurumsal yatırımcılar portföylerine BTC eklemeye devam ediyor.

Blockchain tabanlı AI projeleri ise iki teknolojinin kesişiminde yeni fırsatlar yaratıyor. Merkeziyetsiz veri pazarları, AI'nın açlığını giderebilir.

Wall Street'in hala anlamadığı şey: en büyük teknolojik devrimler her zaman geleneksel finans sistemini bypass ederek gelir. Bitcoin bunun sadece başlangıcı.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

This is even as the Cambridge-based company on Thursday broke the ground on its new $4.5 billion plant in Virginia a day earlier as part of its planned $50 billion investment to ramp up U.S. drug production and research and development. The plant is designed to be its biggest of its facilities around the world.

However, these series of update failed to MOVE AZN shares, which traded in the red zone on Friday afternoon at around $84 per share.

According to reports, AstraZeneca WOULD sell its medications at “most-favored-nation” (MFN) prices that will help bring down their cost, including for Americans on healthcare program Medicaid. However, more broad details of the pricing deal is yet to emerge.

AstraZeneca Trails Rival Pfizer’s Trump Deal

The move follows a similar deal U.S.-based rival Pfizer (PFE) struck with President Trump late last month, with the company obtaining a three-year grace from the administration’s tariffs on the pharmaceutical industry. Trump during the announcement had said his government was also in talks with other pharmaceutical companies for a similar arrangement.

Earlier this week, California-based pharmaceutical Amgen (AMGN) also announced a 60% price cut on its popular low-cholesterol medication, Repatha, and launched a direct-to-consumer drug discount platform. However, the move was not tried to an arrangement with the U.S federal government.

Trump Fights High Drug Prices with Tariffs

The discounts come as President Trump has been clamoring for pharmaceuticals in the country to lower drug prices, using tariffs as a negotiation tool. Trump last month even announced a new 100% tariff on branded drugs imported into America.

It is important to note that during the unveiling of the arrangement with Pfizer, Trump decried that U.S. consumers have been subsidizing research and development costs “for the entire planet.” He urged that pharma businesses made 75% of their profit from the country despite Americans only accounting for 13% of all drug prescriptions.

Earlier in July, the American leader wrote to 17 major pharmaceutical firms, including AstraZeneca, asking that drug prices under Medicaid be sold at MFN prices — or what is equal to or lower than prices in other developed countries.

Is AstraZeneca Stock a Buy or Sell?

Turning to Wall Street, AstraZeneca’s shares currently have a Strong Buy consensus recommendation, as seen on TipRanks. This is based on three Buys assigned by analysts over the past three months. Moreover, the average AZN price target of $92.33 suggests a possible 10% increase from the current position.